R&D in 2020
Quantum Life Sciences invests in biopharmaceutical, specialty pharmaceutical, medical device, healthcare and enabling life science technology companies globally, with a focus on companies that both drive medical innovation across the value chain and enable that innovation to improve the lives of patients with unmet medical needs.
Quantum Life Sciences serves as one of the pillars in our private equity business, and we actively invest in pharmaceutical companies which are aligned with our framework to continuously increase R&D efforts to meet the growing demand for specialty medical needs.
We invest in companies with R&D efforts that include Neurology, Oncology and immunology, and believe that technological advances done by one of our portfolio companies like Schrödinger will assist in the acceleration of the medical advances.
One of our fully owned companies in the healthcare sector is Tandregulering, the leading Orthodontic and Maxillofacial company in Denmark, where we have expanded the capabilities of the company and accelerated growth within a few years to achieve more than a +106% growth p.a, and Ebitda increase of +58%.
The differentiated skillset of Quantum EQT’s team enables it to pursue opportunities created by several longterm trends in healthcare. In particular, these trends are creating an increased need for targeted capital and value-added strategic support of companies around their critical phases of growth, during which they must prove their clinical and business value.
We asses each company rigorously and determine the value we can add to the growth and successful value creation through growth capital and LBO.
Quantum EQT have partnered with Doctors without borders and each year we commit a share of our revenue to support their efforts and work globally.